Clinical trial for Patients With Non-Small Cell Lung Cancer
Official title Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
ClinicalTrials.gov ID: NCT06472245
What this study is testing
What is OSE2101?
An investigational peptidic cancer vaccine being studied as a potential treatment for non‑small cell lung cancer. It is designed to stimulate the immune system to recognize and attack cancer cells by presenting multiple tumor‑associated antigen peptides to HLA‑A2 and HLA‑DR molecules.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to find out if the vaccine OSE2101 works better than the standard chemotherapy drug docetaxel for treating lung cancer that has become resistant to immune checkpoint inhibitors.
- Who it's for
- The study is looking for people with metastatic non-small cell lung cancer who have a specific gene type (HLA-A2 positive) and whose cancer stopped responding to previous immune therapy.
- What's involved
- Participants will be randomly assigned to receive either the OSE2101 vaccine alone or the standard chemotherapy drug docetaxel alone. They will undergo regular medical visits and tests to monitor their health and how the cancer is responding.
- Time commitment
- The study involves regular visits over a period of time to receive treatment and check on progress, though the exact duration is not specified in the provided text.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Male or female, aged ≥ 18 years
- Patients expressing HLA-A2 phenotype in blood by pre-screening central laboratory
- Patients with histologically or cytologically squamous or non-squamous documented NSCLC, metastatic stage at study entry, not eligible for definite...
- Patients with secondary resistance to ICI; Other inclusion and
You likely can't join if
- will apply per protocol.
The study team makes the final eligibility decision.
Where it is enrolling
- Beverly Hills, California, United States
- Wheat Ridge, Colorado, United States
- Norwich, Connecticut, United States
- Washington D.C., District of Columbia, United States
- Fleming Island, Florida, United States
- Jacksonville, Florida, United States
- Jacksonville Beach, Florida, United States
- Saint Augustine, Florida, United States
- St. Petersburg, Florida, United States
- Trinity, Florida, United States
- Chicago, Illinois, United States
- Covington, Louisiana, United States
- Hammond, Louisiana, United States
- Baltimore, Maryland, United States
- Worcester, Massachusetts, United States
- Lincoln, Nebraska, United States
- New Hyde Park, New York, United States
- New York, New York, United States
- Patchogue, New York, United States
- Greenville, South Carolina, United States
+ 116 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Beverly Hills, California, United States; Wheat Ridge, Colorado, United States; Norwich, Connecticut, United States; Washington D.C., District of Columbia, United States; Fleming Island, Florida, United States; Jacksonville, Florida, United States and 130 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.